Cargando…
Recombinant factor VIIa use in patients presenting with intracranial hemorrhage
Recombinant factor VIIa (rFVIIa) can be used for rapid INR normalization in life-threatening hemorrhage in anticoagulated patients. Dosing is unclear and may carry thromboembolic risks. We reviewed the use of rFVIIa at a comprehensive stroke and cerebrovascular center to evaluate dose effectiveness...
Autores principales: | Yampolsky, Natalie, Stofko, Douglas, Veznedaroglu, Erol, Liebman, Kenneth, Binning, Mandy J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155054/ https://www.ncbi.nlm.nih.gov/pubmed/25197623 http://dx.doi.org/10.1186/2193-1801-3-471 |
Ejemplares similares
-
Retrospective study of Heparin Administration for Ischemic Stroke when there is an IV-tPA Contraindication
por: Hakma, Zakaria, et al.
Publicado: (2014) -
Thromboembolic risks of recombinant factor VIIa use in warfarin-associated intracranial hemorrhage
por: Chou, S, et al.
Publicado: (2011) -
Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case–control study
por: H-Y, Chou Sherry, et al.
Publicado: (2012) -
Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
por: Kissela, Brett M, et al.
Publicado: (2008) -
Recombinant Activated Factor VIIa Treatment for Refractory Hemorrhage in Infants
por: Dang, Chi N, et al.
Publicado: (2010)